Key Takeaways
- Margin normalisation, not deterioration: Consolidated EBITDA margin fell to 16.4% from 21.2% QoQ, driven by an inventory accounting unwind and deliberate investment of Barium profits into new market entry, not a structural cost problem.
- Volume engine at full throttle: All-time high production volume, debottlenecking lifting utilisation above 85%, and Barium volumes up ~20% YoY put the company on track for its 30-35% consolidated volume growth trajectory.
- The USA bet is now live and premium: Barium Carbonate sales entered the USA, a market commanding an 8-9% price premium, and the company is now one of its largest suppliers with a clear plan to grow share.
- Backward integration is delivering structural savings: The CO2-to-soda-ash plant hit ~80% utilisation, saving ₹4-4.5 cr/month, a margin tailwind that compounds as the plant reaches optimum levels.
- What to watch next quarter: The detailed CapEx plan promised after Q2 results, any timeline for Barium margin normalisation, and whether the 17.5-18% EBITDA exit rate stays on track.
Margin Walk: The Q1 Dip
- Inventory accounting drove the reset: Q4 FY24 benefited from selling down high finished goods inventory, inflating the change-in-inventory gain. That gain reversed in Q1 FY25 as inventory was rebuilt, mechanically compressing the reported margin back to a normalised run rate.
- Barium profits were reinvested, not lost: A portion of gross profitability from Barium chemistry was deliberately used to price competitively and penetrate premium markets like the USA, depressing the segment's reported gross margin without reflecting any deterioration in its underlying cost structure.
- Structural tailwinds are building beneath the noise: Process improvements cut feedstock consumption by 7-10% in Chromium, the CO2 plant is saving ₹4-4.5 cr/month, and debottlenecking is spreading fixed costs over higher volumes, all of which flow directly to EBITDA given near-constant fixed costs.
- The margin target is back-end loaded: Management aims to consolidate the current 16-17% range and exit FY25 at 17.5-18%, with a medium-term ambition of a consistent 20%, but has explicitly stated it has not guided for 20-21% this year.
Hanumant Bhansali: "We'd like to consolidate this and improve it further by the end of the year to reach to about 17.5%, 18%. But our target in the next 2 to 3 years is to achieve our EBITDA margin consistently at 20%."
The USA Entry & Export Strategy
- Barium Carbonate cracked the premium market: The Barium business forayed into the USA, described as one of the most premium markets after Japan, driving export turnover from ~₹32 crores in Q4 FY24 to ~₹48 crores in Q1 FY25.
- The premium is real and structural: The USA market commands an 8-9% price premium over other export markets, and the company is already one of the largest Barium suppliers there, with management optimistic about increasing share in the coming quarters.
- Competitive strategy is quality-led, not price-led: Management argues that winning in the USA rests on product quality, customer support, packaging and logistics, not discounting, and that the company's position as one of the most efficient and lowest-cost producers globally gives it a sustainable edge without needing to undercut.
- Export mix to hold steady: The domestic-to-export revenue mix is expected to remain around 50:50 for the full year, with exports carrying a 3-5% price premium but a 45-60 day collection cycle.
Hanumant Bhansali: "price sometimes is a camouflage. It can be looked as a great achievement over a period of short term but in the long term, USA market is open to those players like us, like who have improved their entire portfolio in terms of product quality, in terms of customer support, packaging, logistics."
Volume Growth & Capacity Expansion
- Debottlenecking unlocked immediate capacity: A complete debottlenecking exercise lifted existing plant utilisation from 80-81% to over 85% in Q1 FY25, delivering more production volume with the same fixed cost base.
- Chromium capacity is scaling in phases: Sodium dichromate capacity will rise from 80,000 tonnes to ~1 lakh tonnes over the next two years, a 25% increase, with value-added derivative capacities like chromic acid and chrome oxide green also expanding to boost blended realisations.
- Barium volume trajectory is on track: Q1 FY25 production and sales were ~20% higher YoY, consistent with the 30-35% consolidated volume growth trajectory driven by Barium capacity additions, with further momentum expected.
- Global market share ambition is a product-mix story: The target to grow Chromium market share from ~8% to 12-13% globally over 3-4 years is not just about sodium dichromate volume; it blends higher-value derivatives that lift the top line from the same vertical.
- New products are ramping: Precipitated Barium Sulphate launched and is operating at ~40% utilisation, with a target to exit the year at 70-75%, while chrome metal is flagged as an exciting import-substitute opportunity that will follow the current expansion phase.
Hanumant Bhansali: "It's a very exciting product. It's an import substitute and it has a very good future from both Indian consumption as well as global consumption."
Backward Integration & Cost Structure
- CO2-to-soda-ash is a rare structural moat: The plant captures CO2 and converts it into sodium carbonate without procuring additional raw materials, a capability management claims very few companies globally possess, and it is now saving ₹4-4.5 cr/month at ~80% utilisation with further optimisation ahead.
- Soda ash in-sourcing ratio stabilised: In-sourcing of soda ash has settled at ~40%, down from 50%, and management expects to maintain this ratio through the year, reducing exposure to external procurement volatility.
- Feedstock efficiency is compounding: Process and product-level improvements in the Chromium vertical have reduced feedstock consumption by 7-10% across different raw materials, a gain that drops straight to the gross margin line.
Hanumant Bhansali: "There are very few companies globally, not just in India, who are converting carbon dioxide into sodium carbonate or soda ash, as we all know, without necessarily procuring any other raw material to produce the same."
Balance Sheet & Capital Allocation
- Debt is falling fast: Term loans have halved from ₹140 crores (March 2023) to ₹84 crores (March 2024), and at the same run rate are expected to reach ~₹42 crores by year-end, with a debt-to-equity ratio comfortably below 0.5.
- No equity dilution on the table: Management explicitly ruled out an equity fundraise, stating that internal accruals and a healthy balance sheet will fund the upcoming CapEx cycle.
- Inventory build is a Red Sea artefact, not a demand problem: Inventory days jumped to 262 in FY24 from 142 the prior year because the Red Sea crisis added 2-3 weeks of transit time, forcing the company to hold higher raw material and finished goods buffers to ensure supply continuity. Management expects to bring this down as logistics delays ease, though no timeline is given.
- The CapEx plan is still being built: Management is working on a detailed CapEx plan covering FY25 and FY26, exploring both organic and inorganic opportunities, and has committed to sharing it after Q2 results, declining to provide even a provisional number before then.
Hanumant Bhansali: "From a management point of view, we are also equally motivated to share the numbers with you and it will be our efforts to share this CapEx plan with you at the end of our Q2."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin exit rate | Reach 17.5-18% | By end of FY25 |
| Medium-term EBITDA margin | Achieve consistently at 20% | Next 2-3 years |
| Chromium global market share | Grow from ~8% to 12-13% | Next 3-4 years |
| Sodium dichromate capacity | Increase from 80,000 tonnes to ~1 lakh tonnes | Next 2 years |
| Term loan reduction | Reduce to ~₹42 crores from ₹84 crores | By end of FY25 |
| Precipitated Barium Sulphate utilisation | Reach 70-75% | By end of FY25 |
| Overall Barium utilisation | Reach ~70% | By end of FY25 |
| Detailed CapEx plan disclosure | Share plan for FY25 and FY26 | After Q2 FY25 results |
| Domestic-to-export revenue mix | Maintain ~50:50 | Full year FY25 |
| Soda ash in-sourcing ratio | Maintain ~40% | Through FY25 |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Operating revenue (consolidated) | ₹338.8 cr, +13% YoY and +13% QoQ |
| EBITDA (consolidated) | ₹55.6 cr, +9% YoY |
| EBITDA margin (consolidated) | 16.4%, vs 21.2% in Q4 FY24 |
| PAT (consolidated) | ₹30.5 cr, +6% YoY |
| Operating revenue (standalone) | ₹258.2 cr, +3% YoY |
| EBITDA (standalone) | ₹43.8 cr, +3% YoY |
| EBITDA margin (standalone) | 16.96%, vs 17.03% in Q1 FY24 |
| PAT (standalone) | ₹26.3 cr, vs ₹25.5 cr in Q1 FY24 |
| Domestic-to-export sales mix | 50:50, vs 53:47 in FY24 full year |
| Export revenue growth | +20% YoY |
| India business revenue growth | ~5% YoY |
| Barium business operating revenue | >₹80 cr, vs ~₹60 cr in Q4 FY24 |
| Chromium chemicals capacity utilisation | >85%, vs 80-81% previously |
| Barium chemicals capacity utilisation | 50-60% range |
| CO2 plant utilisation | ~80% of optimum levels |
| Savings from CO2 plant | ₹4-4.5 cr per month |
| In-sourcing of soda ash | Close to 40%, down from 50% |
| Interest expense | ₹9.12 cr, vs ₹9.24 cr in Q4 FY24 |
| Term loans from banks | ₹84 cr as of 31 March 2024, expected ~₹42 cr by year-end |
| Global market share in Chromium chemistry | ~8%, target 12-13% in 3-4 years |
| India market share in Chromium chemistry | 60% |
| USA share of consolidated turnover | 4-4.5%, up ~300 bps from FY21 |
| US price premium vs other export markets | 8-9% higher |
| Sodium dichromate installed capacity | 80,000 tonnes, plan to reach ~1 lakh tonnes in 2 years |
| Barium installed capacity | 90,000 tonnes as of 31 March |
| Precipitated Barium Sulphate utilisation | ~40%, expected 70-75% by year-end |
| Chromium chemicals optimum revenue range | ₹1,100 cr to ₹1,250 cr |
| Barium vertical optimum revenue range | ₹300 cr to ₹400 cr |
| Debt-to-equity ratio | Less than 0.5 |
| Gross block | ~₹947 cr as of 31 March 2024, vs ~₹735 cr in FY23 |
| Replacement CapEx in Chromium chemicals | ~₹45 cr |